Par Drugs and Chemicals Limited share price

Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, magnesium aluminometasilicate, magnesium aluminosilicate-USP, magnesium oxide light, magnesium oxide heavy, magnesium aluminium hydrate, hydrotalcite, and synthetic aluminium silicate. It offers fine chemicals, such as precipitated silica, sodium aluminium silicate, amorphous aluminium hydroxide, Alu…Read more

Website NSE हिंदी में BSE

HealthcareDrug Manufacturers - Specialty & GenericNSE: PARISIN INE04LG01015

16 Oct 2026, 3:20 PM IST₹109.53▼ 1.69 (1.52%)

Market Cap₹ 135 Cr.
Current Price₹ 109.53
High / Low₹ 180 / 78
Stock P/E10.3
Book Value₹ 91
Dividend Yield0.00 %
ROCE15.0 %
ROE12.40 %
Face Value₹ 10.0

More figures (10)

EPS (TTM)₹ 10.65
Price / Book1.21
OPM12.5 %
Debt / Equity0.00
Sales growth (3Y)2.7 %
Profit growth (3Y)5.0 %
Promoter holding—
EV / EBITDA4.7
Beta0.42
All-time high₹ 348

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
PAR	-13.88%	+15.26%	+17.21%	+8.17%	+7.20%	-18.62%	-16.30%
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Par Drugs and Chemicals Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹135 crore.
It trades at 10.3 times its last 12 months' earnings and 1.2 times book value.
Revenue grew 2.7% a year over the last 3 years, profit 5.0% a year.
Return on equity was 12.4% and return on capital employed 15.0% in the latest year.
Debt was 0.00 times shareholders' equity.
The share price is 39.2% below its 52-week high and up 7.2% over one year.

Pros

Company is almost debt-free (debt is 0.00 times equity).
Latest quarter (Jun 2026): sales up 20% and profit up 42% from a year ago.
Healthy return on equity of 15.1% on average over the last 3 years.
Promoters hold a large stake of 73.41%.

Cons

Sales growth has been slow: 2.7% a year over the last 3 years.
Profit growth has been weak: 5.0% a year over the last 3 years.
The company has not paid a dividend recently.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Par Drugs and Chemicals Limited

Employees: 118
Head office: Vadodara

HealthcareDrug Manufacturers - Specialty & Generic

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Par Drugs and Chemicals	109.53	10.3	135	0.00	5	41.60	31	20.10	15.0	12.4	1.21	12.5	0.00	—	104	2.7
2.	Sun Pharmaceutical Industries	1,758.80	34.9	4,21,995	0.91	2,895	34.65	15,184	18.48	17.9	14.7	5.05	23.4	0.06	55.61	58,220	10.4
3.	Divi's Laboratories	9,144.50	83.0	2,42,758	0.33	902	36.25	3,080	19.15	19.0	16.2	14.48	28.4	0.00	52.00	10,476	11.0
4.	Torrent Pharmaceuticals	4,558.90	72.8	1,73,406	0.83	566	3.28	4,921	54.85	9.1	27.1	18.39	25.0	1.79	63.18	13,980	13.3
5.	Zydus Lifesciences	1,123.00	25.0	1,12,020	0.09	940	-19.74	7,802	24.03	19.0	19.7	4.17	21.7	0.46	75.18	26,720	16.5
6.	Laurus Labs	2,060.10	101.8	1,11,310	0.12	362	123.94	2,026	29.10	19.5	18.2	20.98	19.4	0.48	32.03	6,813	3.8
7.	Cipla	1,325.10	31.8	1,07,051	0.98	789	-35.42	7,077	7.26	14.9	11.8	3.11	17.5	0.02	31.13	27,712	7.2
8.	Dr. Reddy's Laboratories	1,233.00	31.0	1,02,707	0.66	444	-68.72	8,071	-5.56	14.2	12.1	2.68	14.9	0.21	30.14	33,593	11.0
9.	Aurobindo Pharma	1,666.90	26.0	95,910	0.00	1,033	14.29	9,106	8.65	13.5	9.9	2.56	15.6	0.21	54.79	33,385	10.7
10.	Mankind Pharma	2,275.50	46.0	93,988	0.00	568	35.00	4,031	30.89	13.7	12.5	5.76	19.9	0.39	75.39	14,278	17.7
	Median: 47 Co.	1,712.85	31.4	17,624	0.33	679	24.47	5,999	19.62	15.0	14.1	4.17	16.1	0.21	54.79	20,499	13.3

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Standalone figures in ₹ crore

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	23	26	24	23	23	35	21	22	26	29	29	20	31
YOY Sales Growth %		4.31%	4.65%	-6.83%	-1.44%	33.88%	-10.91%	-2.14%	15.22%	-17.31%	37.22%	-12.18%	20.10%
	19	19	19	17	18	23	20	20	22	23	23	18	25
Material Cost %	42%	35%	33%	32%	33%	35%	41%	44%	44%	37%	42%	45%	44%
Employee Cost %	5%	5%	6%	8%	6%	4%	6%	9%	5%	5%	5%	10%	5%
Other Expenses %	35%	32%	40%	34%	43%	28%	46%	37%	37%	37%	32%	37%	30%
Operating Profit	4	7	5	6	4	11	1	2	4	6	6	1	6
OPM %	18%	28%	22%	27%	19%	33%	7%	11%	14%	21%	21%	7%	20%
Other Income	0	0	0	-0	0	1	0	1	2	0	1	0	1
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	1	1	1	1	1	1	1	1	1	1	1	1	1
Profit before tax	3	7	5	5	3	11	1	2	4	6	6	1	6
	25%	25%	25%	27%	25%	25%	25%	28%	26%	26%	26%	-3%	26%
Current tax	1	2	1	1	1	3	0	1	1	1	2	0	2
Deferred tax				0				0				-0
	2	5	3	4	3	9	1	2	3	4	5	1	5
YOY Profit Growth %		31.32%	83.20%	7.91%	2.66%	75.72%	-83.11%	-55.61%	31.38%	-51.96%	729.97%	-48.30%	41.60%
EPS in Rs	2.01	3.97	2.78	3.02	2.06	6.99	0.47	1.34	2.70	3.36	3.90	0.69	3.83
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Standalone figures in ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	75	96	96	101	104	109
YOY Sales Growth %		27.54%	-0.11%	5.58%	2.66%
	59	78	73	81	87	89
Material Cost %	38%	42%	35%	38%	42%	42%
Employee Cost %	5%	5%	6%	6%	6%	6%
Other Expenses %	34%	34%	35%	37%	36%	34%
Operating Profit	16	18	23	20	17	20
OPM %	22%	19%	24%	19%	17%	18%
Other Income	0	0	0	2	4	3
Interest	0	0	0	0	0	0
Depreciation	3	3	3	4	4	4
Profit before tax	13	15	20	18	17	19
	27%	25%	26%	25%	24%	24%
Current tax	3	4	5	5	5
Deferred tax	0	-0	0	0	-0
	9	11	15	13	13	14
YOY Profit Growth %		22.99%	27.94%	-7.88%	-1.87%
EPS in Rs	7.49	9.21	11.78	10.86	10.65	11.78

Compounded Sales Growth

3 Years:: 3%
TTM:: 4%

Compounded Profit Growth

3 Years:: 5%
TTM:: 2%

Stock Price CAGR

5 Years:: -16%
3 Years:: -19%
1 Year:: 7%

Return on Equity

4 Years:: 15%
Last Year:: 12%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	12	12	12	12
Reserves	59	73	87	100
	18	16	20	17
Trade payables	8	5	11	8
Current liabilities	14	12	17	14
Total Liabilities	89	102	119	129
	39	41	39	37
Gross block	68	74	75	77
Accumulated depreciation	29	33	36	40
CWIP	0	0		1
	50	60	80	91
Inventories	5	4	6	5
Trade receivables	17	14	17	12
Cash & equivalents	22	37	28	42
Current assets	49	60	55	64
Total Assets	89	102	119	129

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	13	20	16	16
Profit for the year	11	15	13	13
Working capital changes	-0	2	0	2
Direct taxes paid	-4	-4	-5	-5
	-7	-6	-25	-2
Fixed assets purchased	-8	-6	-1	-2
Fixed assets sold	0	0		0
Investments purchased		-0	-25	-2
	-0
Interest paid	-0
Net Cash Flow	6	14	-9	14
Free Cash Flow	6	14	15	14

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	15.9%	18.5%	14.5%	12.4%
ROCE	—	20.1%	21.9%	17.4%	15.0%
Operating margin	—	15.3%	21.2%	15.6%	12.5%
Net margin	—	11.9%	15.2%	13.3%	12.8%
Debt / equity	—	0.00	0.00	0.00	0.00
Current ratio	—	3.53	4.79	3.31	4.68
Debtor days	—	65	53	61	43
Inventory days	—	30	26	33	27
Days payable	—	44	33	59	41
Cash conversion cycle	—	51	46	35	29
Working capital days	—	136	181	139	180

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 73.41%
DIIs 0.09%
Public 26.51%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	74.21%	74.21%	74.21%	73.37%	73.37%	73.37%	73.37%	73.37%	73.41%	73.41%	73.41%	73.41%
	0.07%	0.07%	0.32%	0.09%
Foreign portfolio investors (Cat. II)	0.07%	0.07%	0.32%	0.09%
		0.05%									0.09%	0.09%
Alternative investment funds		0.05%									0.09%	0.09%
	25.73%	25.68%	25.47%	26.54%	26.63%	26.63%	26.63%	26.63%	26.59%	26.59%	26.51%	26.51%
Retail (up to ₹2 lakh)	17.07%	16.66%	15.05%	14.51%	20.95%	18.71%	19.10%	18.94%	18.89%	18.81%	18.59%	18.19%
HNIs (above ₹2 lakh)	4.16%	3.79%	5.04%	4.91%	1.91%	1.59%	1.16%	1.33%	1.14%	1.16%	1.36%	1.45%
NRIs	1.31%	1.20%	1.12%	1.21%	1.19%	1.03%	1.09%	1.12%	1.10%	1.09%	1.07%	1.09%
Bodies corporate	1.03%	1.81%	2.80%	4.72%	1.39%	2.95%	3.22%	3.18%	3.27%	3.29%	3.26%	4.18%
No. of Shareholders	7,020	7,403	8,022	8,757	17,189	15,472	14,887	14,280	13,761	13,222	12,782	12,672

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

None filed recently.

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 22 Nov 2021
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Par Drugs and Chemicals Limited

What is the share price of Par Drugs and Chemicals Limited today?

Par Drugs and Chemicals Limited (PAR) last traded at ₹109.53 on NSE (16 Oct 2026, 3:20 PM IST). Prices may be delayed.

What is the market cap of Par Drugs and Chemicals Limited?

About ₹135 crore at the latest price.

What is the P/E ratio of Par Drugs and Chemicals Limited?

About 10.3 times its earnings over the last 12 months.

Is Par Drugs and Chemicals Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Par Drugs and Chemicals Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.